Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Protein Expression of Matriptase and its Cognate Inhibitor HAI-1 in Human Prostate Cancer A Tissue Microarray and Automated Quantitative Analysis

Protein Expression of Matriptase and its Cognate Inhibitor HAI-1 in Human Prostate Cancer A... RESEARCH ARTICLE Protein Expression of Matriptase and its Cognate Inhibitor HAI-1 in Human Prostate Cancer A Tissue Microarray and Automated Quantitative Analysis Miranda Warren, BS,* Matthew Twohig, MD,* Thomas Pier, BS,* Jens Eickhoff, PhD,w Chen-Yong Lin, PhD,zy David Jarrard, MD,J and Wei Huang, MD* Key Words: matriptase, prostate cancer, hepatocyte growth factor Abstract: Recent studies have suggested that matriptase, a activator inhibitor-1, AQUA transmembrane serine protease and its cognate inhibitor (Appl Immunohistochem Mol Morphol 2009;17:23–30) hepatocyte growth factor activator inhibitor-1 (HAI-1) are important in the progression of many cancers. Limited quantitative data are available on these proteins in prostate cancer. To validate the roles of matriptase and HAI-1 in rostate cancer is the most common nondermatologic prostate cancer and its progression, a prostate cancer tissue Pcancer for men (29% of all cancers) in the United microarray was constructed. The tissue microarray includes 41 States. After lung cancer, prostate cancer is the leading localized prostate cancers (Pca_local), 18 aggressive prostate cause of cancer-related deaths (9% of all cancer deaths) cancers, 18 metastatic prostate cancers, 24 benign prostate among men in the United States. Early detection of prostate cancer has increased because of the prostate- hyperplasias, 18 high-grade intraepithelial neoplasias (HGPIN), http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Protein Expression of Matriptase and its Cognate Inhibitor HAI-1 in Human Prostate Cancer A Tissue Microarray and Automated Quantitative Analysis

Loading next page...
 
/lp/wolters-kluwer-health/protein-expression-of-matriptase-and-its-cognate-inhibitor-hai-1-in-WhlTNdi5Gw
ISSN
1541-2016
DOI
10.1097/PAI.0b013e31817c3334
pmid
18813126
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE Protein Expression of Matriptase and its Cognate Inhibitor HAI-1 in Human Prostate Cancer A Tissue Microarray and Automated Quantitative Analysis Miranda Warren, BS,* Matthew Twohig, MD,* Thomas Pier, BS,* Jens Eickhoff, PhD,w Chen-Yong Lin, PhD,zy David Jarrard, MD,J and Wei Huang, MD* Key Words: matriptase, prostate cancer, hepatocyte growth factor Abstract: Recent studies have suggested that matriptase, a activator inhibitor-1, AQUA transmembrane serine protease and its cognate inhibitor (Appl Immunohistochem Mol Morphol 2009;17:23–30) hepatocyte growth factor activator inhibitor-1 (HAI-1) are important in the progression of many cancers. Limited quantitative data are available on these proteins in prostate cancer. To validate the roles of matriptase and HAI-1 in rostate cancer is the most common nondermatologic prostate cancer and its progression, a prostate cancer tissue Pcancer for men (29% of all cancers) in the United microarray was constructed. The tissue microarray includes 41 States. After lung cancer, prostate cancer is the leading localized prostate cancers (Pca_local), 18 aggressive prostate cause of cancer-related deaths (9% of all cancer deaths) cancers, 18 metastatic prostate cancers, 24 benign prostate among men in the United States. Early detection of prostate cancer has increased because of the prostate- hyperplasias, 18 high-grade intraepithelial neoplasias (HGPIN),

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Jan 1, 2009

There are no references for this article.